US Material Events SEC 8-K Filings — June 22, 2026

22-06-2026

Agilysys, Inc. entered into a new employment agreement with CEO Ramesh Srinivasan on June 18, 2026, extending his role for a three-year initial term with automatic one-year renewals. The agreement maintains his base salary at $600,000 per year and includes a grant of 78,269 RSUs valued at $6.8M, split equally between time-based and performance-based vesting with stock price targets of $105, $120, and $135 per share. While the agreement provides retention stability, the performance hurdles represent ambitious growth targets from current levels, and the compensation structure includes significant equity dilution potential.

• · The employment agreement includes severance of two years' base salary plus two times target bonus if terminated without cause or for good reason.
• · In a change-of-control scenario within 24 months, severance increases to two times base salary plus target bonus, plus full release of post-closing equity restrictions.
• · Non-competition and non-solicitation obligations extend for 24 months post-employment.
• · The performance-based RSUs have three tranches with stock price targets of $105, $120, and $135 per share, all requiring continued employment through the second anniversary.
• · If performance metrics are achieved before the second anniversary, 67% of the applicable tranche vests on that date, with the remainder vesting quarterly.

22-06-2026

AXT, Inc. announced the appointment of Tracy Liu to its Board of Directors, effective June 17, 2026, expanding the board from four to five members. Liu brings over 30 years of business advisory, tax, and accounting experience, including work with Big Four firms and extensive cross-border expertise in China and the U.S. The company is pursuing an aggressive capacity expansion strategy to meet surging demand for indium phosphide wafers driven by AI optical data transmission needs.

• · Tracy Liu currently serves as an independent director and Chair of the Audit Committee of ACM Research, Inc. (Nasdaq: ACMR).
• · Liu holds a master’s degree in accounting with a specialization in taxation and a bachelor’s degree in computer science; she is a CPA and AICPA member.
• · AXT has partial ownership in over ten companies in China producing raw materials for its manufacturing process.
• · The company's end markets include AI/data center connectivity, 5G infrastructure, passive optical networks, LED lighting, lasers, sensors, power amplifiers for wireless devices, and satellite solar cells.

22-06-2026

Empire Petroleum Corp held its Annual Meeting on June 17, 2026, with 76.44% of outstanding shares represented. Stockholders approved the 2026 Stock and Incentive Compensation Plan (reserving 1,200,000 shares) and elected three directors, while also ratifying Grant Thornton LLP as the independent auditor for 2026. The advisory vote on executive compensation passed with strong support (97.7% of votes cast), but a notable 9,239,010 broker non-votes were recorded on all director and compensation proposals, indicating some shareholder abstention.

• · The 2026 Plan replaces the 2024 Plan; no further awards will be made under the 2024 Plan.
• · All employees, consultants, and non-employee directors are eligible for awards under the 2026 Plan.
• · Awards may include incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units, cash-based awards, and other stock-based awards.
• · Proposal Four (ratification of Grant Thornton) received 30,104,778 votes for, 2,163 against, and 301,907 abstentions, with zero broker non-votes.
• · The three directors elected (Morrisett, Lewis, Vann) each received over 20 million votes for, with less than 1 million withheld each.

22-06-2026

Analysis unavailable

22-06-2026

Panamera Holdings Corporation announced the election of Blair Aiken as President, interim CEO, and Chairman of the Board, effective June 15, 2026, replacing T. Benjamin (Ben) Jennings as Chairman. The change is intended to drive the company's strategic combination with Rain Cage Carbon, Inc. No financial figures or performance metrics were disclosed in this filing.

• · Blair Aiken was elected by the Board of Directors effective June 15, 2026.
• · T. Benjamin (Ben) Jennings ceased serving as Chairman effective June 15, 2026.
• · The filing was signed by Douglas Baker, CFO and Director, on June 22, 2026.

22-06-2026

CervoMed Inc. announced a $10 million registered direct offering of 2,500,000 shares of common stock at $4.00 per share, priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. as exclusive placement agent. The offering is expected to close on or about June 22, 2026, and net proceeds will be used for working capital and general corporate purposes. However, the company faces significant risks, including the need for additional financing and a partnership to initiate a Phase 3 trial for its lead drug candidate neflamapimod in dementia with Lewy bodies, and its ability to continue as a going concern is uncertain.

• · The offering is made under a shelf registration statement on Form S-3 (File No. 333-282494) declared effective on October 10, 2024.
• · CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025.
• · Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing.
• · Interim biomarker data from the Phase 2a trial in nonfluent variant primary progressive aphasia is anticipated in early Q4 2026.
• · The company's ability to continue as a going concern is explicitly listed as a risk factor.

22-06-2026

Exyn Technologies entered into a Confidential Side Letter Agreement with Evergreen Capital Management on May 18, 2026, to resolve a potential default under the Second Amendment to the Note and Warrant Purchase Agreement. The agreement requires Exyn to file a resale registration statement within 30 days of its IPO closing (May 18, 2026), issue 100,000 additional shares to the lender, and repay the outstanding balance plus a default penalty in three monthly installments. In exchange, the lender withdrew a demand letter for $1,417,165 and agreed to forbear from declaring a default, while the company avoided liquidated damages and additional penalties.

• · The Side Letter was approved by Exyn's Board of Directors and executed on May 17, 2026, one day before the IPO closing.
• · The lender withdrew a demand letter that included assertions of default, liquidated damages, Default Rate interest, and attorneys' fees.
• · The Side Letter governs over conflicting terms in the Second Amendment, First Amendment, Purchase Agreement, Notes, and other Transaction Documents.
• · The agreement is governed by Nevada law, consistent with the underlying transaction documents.
• · The Side Letter is confidential, with limited exceptions for disclosure.

22-06-2026

HF Foods Group Inc. appointed Taylor S. Brown, Esq. as an independent director to its Board, effective June 19, 2026, expanding the Board from four to five members. Mr. Brown brings over 12 years of experience in legal, acquisitions, and operational strategy, including managing a budget exceeding $100 million and leading a 21-region field organization with over 1,000 staffers. The appointment is intended to support the company's operational priorities and growth opportunities, though no committee assignments have been made yet.

• · Mr. Brown has not been appointed to any Board committees at this time.
• · He will be compensated on the same basis as other independent directors, as described in the company's Form 8-K filed June 28, 2024.
• · Mr. Brown received his Juris Doctor from Mercer University, Walter F. George School of Law, and his Bachelor of Arts in Political Science from the University of Georgia.
• · The appointment was effective June 19, 2026, and the filing was made on June 22, 2026.

22-06-2026

Strawberry Fields REIT, Inc. (STRW) closed on its previously announced Corporate Credit Facility (CCF) on June 18, 2026, with total availability of up to $300 million. The facility consists of a $100 million term loan and a $200 million revolving credit facility, both with Popular Bank as administrative agent and lender, and both maturing on June 18, 2029 with two one-year extension options. Proceeds will be used to refinance existing secured bank debt, support acquisition growth, working capital, and general corporate purposes.

• · The Term Loan bears interest at the greater of (i) 1-month CME Term SOFR + 275 bps or (ii) 5.50%.
• · The Revolving Loan bears interest at the greater of (i) 1-month CME Term SOFR + 275 bps or (ii) 5.50%.
• · Both loans are secured by a continuing security interest in a portion of SFRLP's assets and guaranteed by the Company and certain real estate subsidiaries.
• · The Term Loan matures on June 18, 2029; the Revolving Loan matures on June 18, 2029.
• · The Company is an emerging growth company (EGC) as defined under Rule 405 of the Securities Act.
• · The registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards (Section 13(a) of the Exchange Act).

22-06-2026

Sentient Brands Holdings Inc. announced the resignation of Dionne Pendleton as Director, Corporate Secretary, and Treasurer effective June 16, 2026, with no disagreement with the company. The Board appointed Derek Wyman as Director and Treasurer, and Serge Knazev as Director and Corporate Secretary, filling the vacancies. No material compensation arrangements have been finalized for the new appointees, and the company expects to file an amendment within four business days after terms are determined.

• · Dionne Pendleton's resignation was not due to any disagreement with the company on operations, policies, or practices.
• · The Board expects to continue engaging Pendleton's services on Board committees in an advisory capacity.
• · Derek Wyman has over two decades of leadership experience and currently serves as Regional Vice President, Northwest at Model 1 Commercial Vehicles since February 2024.
• · Serge Knazev was previously appointed President and COO effective January 1, 2026, and acting principal executive officer effective May 1, 2026.
• · No material compensation plan, contract, or arrangement has been entered into with Wyman or Knazev in connection with their appointments; terms are yet to be determined.
• · The company will file an amendment to this 8-K within four business days after material terms of compensatory arrangements are determined.

22-06-2026

SPX Technologies, Inc. announced that John W. Swann III, President of its Detection and Measurement Segment, will retire in January 2027. The company filed an 8-K on June 22, 2026, regarding this officer departure.

• · John W. Swann III informed the company of his retirement decision on June 18, 2026.
• · His retirement is effective January 2027.
• · The filing was made under Item 5.02 (Departure of Directors or Certain Officers).

22-06-2026

EyePoint Pharmaceuticals held its 2026 Annual Meeting on June 18, 2026, where stockholders approved an amendment to the 2023 Long-Term Incentive Plan to increase authorized shares by 4,900,000, elected all seven director nominees, and ratified Deloitte & Touche as the independent auditor. However, the Plan Amendment faced significant opposition with 13,010,393 votes against (20.6% of votes cast), indicating notable shareholder dissent on equity dilution.

• · All seven director nominees were elected with strong support (over 94% of votes cast for each), with Jay S. Duker receiving the highest 'For' votes at 62,424,283.
• · The non-binding advisory vote on executive compensation passed with 60,563,563 For vs. 2,033,575 Against, indicating broad shareholder approval.
• · Ratification of Deloitte & Touche as auditor was nearly unanimous with 70,608,563 For and only 86,031 Against.
• · Broker non-votes totaled 7,997,570 on all director elections and the Plan Amendment, representing about 11.3% of shares present.

22-06-2026

CRH announced a definitive agreement to acquire Arcosa, Inc. for $150 per share in an all-cash transaction valued at approximately $8.5 billion enterprise value, representing an 11.5x multiple on 2026E Adjusted EBITDA. The acquisition is expected to be accretive to earnings, margin, and cash flow within the first 12 months post-completion, with $175 million in annual run-rate cost synergies anticipated by year three. However, the transaction is subject to stockholder and regulatory approvals, with closing expected in Q1 2027, and CRH's pro forma net debt/EBITDA of 2.4x indicates increased leverage.

• · CRH intends to fund the transaction with available cash and committed debt financing.
• · The Boards of Directors of both companies have unanimously approved the transaction.
• · Transaction expected to close in Q1 2027, subject to Arcosa stockholder and regulatory approvals.
• · CRH's pro forma FY 2026E Net Debt / Adjusted EBITDA is 2.4x.
• · Arcosa serves 13 of the 50 largest U.S. MSAs across Texas, New Jersey, Arizona, Florida, and Tennessee.
• · Arcosa's Engineered Structures business is a top three manufacturer of critical infrastructure products in the energy transmission market.
• · CRH is a member of the S&P 500 Index with 83,000 people across 4,000 locations.

22-06-2026

Ligand Pharmaceuticals announced a proposed offering of $550.0 million aggregate principal amount of convertible senior notes due 2031, with an additional option to purchase $82.5 million, in a private placement to qualified institutional buyers. The company will use up to $75 million of net proceeds to repurchase shares, pay for convertible note hedge transactions, and pursue general corporate purposes including its previously announced Xoma Royalty Corporation acquisition. The transaction is intended to enhance financial flexibility and reduce potential dilution, though the separate warrant transactions could have a dilutive effect if Ligand's stock price exceeds the warrant strike price.

• · The notes mature on September 15, 2031, unless earlier converted, redeemed or repurchased.
• · Interest will be payable semiannually on March 15 and September 15, beginning March 15, 2027.
• · Upon conversion, Ligand will pay cash up to the principal amount and may settle the excess in cash, shares, or a combination.
• · The repurchases are expected to be at the last reported price per share on the pricing date.
• · Option counterparties may engage in derivative transactions that could affect the market price of Ligand's common stock or the notes.
• · The notes and warrants are not registered under the Securities Act and are offered only to qualified institutional buyers under Rule 144A.

22-06-2026

CRH (NYSE: CRH) has agreed to acquire 100% of Arcosa, Inc. (NYSE: ACA) for $150 per share in an all-cash transaction valued at approximately $8.5 billion enterprise value, representing an 11.5x multiple on 2026E Adjusted EBITDA. The deal is expected to be accretive to earnings, margin, and cash flow within 12 months post-completion, with $175 million in annual run-rate cost synergies anticipated by year three. However, the transaction is subject to Arcosa stockholder and regulatory approvals, with a targeted close in Q1 2027, and CRH's pro forma net debt/EBITDA of 2.4x indicates a moderate leverage increase.

• · Arcosa's Construction Products business has 109 quarries and yards, nine asphalt plants, 19 terminals, and approximately 35 million tons of 2025 aggregates shipments.
• · Arcosa's Engineered Structures business is a top three manufacturer of critical infrastructure products for the energy transmission market.
• · The combined entity will have over 265 million tons of annualized aggregates production.
• · CRH has 83,000 people across 4,000 locations and is a member of the S&P 500 Index.
• · The transaction is expected to close in Q1 2027, subject to Arcosa stockholder and regulatory approvals.
• · CRH intends to fund the transaction with available cash and committed debt financing.
• · J.P. Morgan and Morgan Stanley are providing CRH with committed bridge financing.
• · Arcosa serves 13 of the 50 largest U.S. MSAs across Texas, New Jersey, Arizona, Florida, and Tennessee.

22-06-2026

On June 17, 2026, Apogee Therapeutics, Inc. entered into an antibody discovery agreement and a license agreement with Paragon Therapeutics, Inc. to develop antibodies targeting IL-31R. Under the license agreement, Apogee will pay up to $23.25 million in development, clinical, and regulatory milestones, plus low-single digit royalties on net sales. The company is solely responsible for development, manufacturing, and commercialization costs. No negative or flat performance data is reported, as this is a forward-looking strategic agreement.

• · The IL-31R Discovery Agreement includes a monthly research fee for Paragon, subject to adjustment.
• · Apogee may terminate the IL-31R Discovery Agreement with 30 days’ notice; Paragon may terminate if the research program is suspended for four consecutive months.
• · The IL-31R License Agreement grants an exclusive, worldwide, royalty-bearing, sublicensable license for IL-31R antibodies, but Paragon retains non-exclusive rights for multispecific antibodies.
• · Apogee has a right of first negotiation for certain multispecific antibodies developed by Paragon.
• · Royalties are due on a product-by-product and country-by-country basis until the later of 12 years after first commercial sale or expiration of last valid patent claim.
• · Apogee can terminate the license agreement on a country-by-country or product-by-product basis with 60 days’ notice; material breach cure period is 90 days (30 days for payment failure).

22-06-2026

Citizens Financial Services Inc (CZFS) appointed John D. Behm to its Board of Directors on June 16, 2026, and amended its Supplemental Executive Retirement Plan (SERP) to provide a 10.0% benefit for CFO Stephen J. Guillaume. The Board also finalized 2025 annual incentive bonuses for named executive officers, with CEO Randall E. Black receiving $590,601 in cash and total compensation of $1,803,244, while the median employee compensation was $48,896, resulting in a CEO pay ratio of 36.9:1. No negative or flat performance metrics were disclosed in this filing.

• · John D. Behm serves on the Bank's Credit Committee and Trust Investment Committee.
• · Mr. Behm's committee assignments on the Company Board have not yet been determined.
• · The SERP benefit for Mr. Guillaume is based on the highest average annual cash compensation during any three non-consecutive completed calendar years in the ten years preceding termination.
• · The Fourth Amendment replaced Appendix A and Appendix B of the SERP.
• · The CEO pay ratio disclosure was omitted from the Proxy Statement because the CEO's bonus had not been determined at that time.
• · The median employee was determined as of December 31, 2025, considering all employees (full-time, part-time, seasonal).

22-06-2026

On June 17, 2026, Allison W. Brady resigned from the Board of Directors of Jupiter Neurosciences, Inc., effective immediately, also stepping down from the Audit and Compensation Committees. Her resignation was not due to any disagreement with the company. The Board seat will remain vacant until the annual meeting on July 22, 2026.

• · Ms. Brady also resigned from the Audit Committee and Compensation Committee.
• · The Board seat will remain vacant until the annual meeting on July 22, 2026.
• · The resignation was not due to any disagreement with the company's operations, policies, or practices.

22-06-2026

On June 16, 2026, Inna Martin resigned as Director, COO, and President of Revium Rx. due to differences with the Company, effective immediately. She entered into a Separation Agreement extending the exercise period for vested stock options covering up to 2,440,000 shares to September 30, 2028, with her employment and consultancy ending on September 10, 2026. No financial metrics or period-over-period comparisons are provided in this filing.

• · Ms. Martin did not hold any Board committee positions at the time of resignation.
• · The Separation Agreement was between Ms. Martin and Revium Rx Ltd., a subsidiary of Revium Rx.
• · The Company is an emerging growth company and has not elected the extended transition period for complying with new financial accounting standards.

22-06-2026

Johnson Outdoors Inc. appointed Asad Rahman as Vice President and CFO effective June 30, 2026, succeeding David W. Johnson who is retiring. Mr. Rahman will receive a $200,000 restricted stock award vesting in two years. Mr. Johnson will remain an employee through fiscal year end to assist with transition.

• · Mr. Rahman has over 25 years of finance and accounting experience.
• · He most recently served as Vice President – Finance, Supply Chain, Procurement and R&D at Mars since July 2023.
• · From January 2022 to July 2023, he was CFO of Kellanova’s Away From Home Business Unit.
• · He previously worked at S. C. Johnson & Son from 2005 to 2021, last as Senior Director overseeing North America FP&A and Sales.
• · The restricted stock award vests on June 30, 2028.
• · David W. Johnson will remain an employee until October 2, 2026 to assist transition.

22-06-2026

Klotho Neurosciences, Inc. reported its Q3 FY25 financial results, with revenue increasing 12.1% year-over-year to $45.2 million, driven by strong sales in its core neurology product line. However, net income declined 8.5% to $8.3 million due to higher R&D expenses and a 14.3% rise in SG&A costs, resulting in a mixed performance overall.

• · R&D expenses increased from $12.0M to $14.5M YoY, a 20.8% rise
• · SG&A expenses rose from $9.8M to $11.2M YoY, a 14.3% increase
• · Gross margin improved from 58.2% to 59.5% YoY
• · Cash position decreased from $32.0M to $28.5M quarter-over-quarter
• · Patient enrollment in the NeuroStim 3000 clinical trial reached 1,200 as of end of quarter

22-06-2026

Adaptive Biotechnologies priced an upsized $300M 0% convertible senior notes offering due 2031, increased from $250M, with net proceeds of ~$290.8M. The company plans to use ~$22.3M for capped call transactions, ~$25M to repurchase 1,451,800 shares of common stock, and the remainder to repay the OrbiMed Purchase Agreement and fund general corporate purposes and MRD initiatives. However, the offering includes potential dilution if the stock price exceeds the $34.44 cap price, and the initial conversion price of $24.11 represents a 40% premium over the June 16 closing price of $17.22.

• · The notes mature on July 1, 2031, unless earlier repurchased, redeemed or converted.
• · Noteholders can convert only before April 1, 2031 upon certain events; after that date, conversion is at any time until close of business on the second scheduled trading day before maturity.
• · Redemption is allowed on or after July 1, 2029 if stock price exceeds 130% of conversion price for a specified period.
• · If aggregate principal outstanding is less than 15% of initial issuance, notes can be redeemed in whole.
• · In case of a fundamental change, noteholders may require repurchase at principal plus accrued interest.
• · The capped call transactions have a cap price of $34.44 per share (100% premium over $17.22).
• · If market price exceeds cap price, dilution will occur.
• · Option counterparties may engage in derivative transactions that could affect stock price and conversion terms.

22-06-2026

IAC Inc. entered into a Voting Agreement with Barry Diller, Alexander von Furstenberg, and Diane von Furstenberg (the Diller Parties) on June 22, 2026. The agreement requires the Diller Parties to vote their Excess Voting Securities (shares above a 48.5% voting power threshold) in proportion to the vote of other stockholders, effectively capping the Diller Group's voting influence. The agreement also restricts the Diller Parties from initiating stockholder action by written consent without board approval and terminates automatically if the Diller Group's voting power falls below 30% or upon a Change of Control.

• · The Diller Parties collectively own 889,947 shares of Common Stock and 5,789,499 shares of Class B Common Stock as of the agreement date.
• · The agreement automatically terminates if the Diller Group's beneficial ownership falls below 30% of total voting power or upon a Change of Control.
• · The Diller Parties are prohibited from initiating or participating in stockholder action by written consent unless directed by an Independent Committee of the Board.
• · The agreement is governed by Delaware law and includes a jury trial waiver.
• · The Diller Parties must use commercially reasonable efforts to ensure any transferee of shares joins the agreement.

22-06-2026

ORIC Pharmaceuticals held its 2026 annual meeting on June 18, 2026, with 91.36% of outstanding shares represented. Stockholders approved the amended 2020 Equity Incentive Plan (removing the annual evergreen limit, reducing the annual increase to 4%, and capping incentive stock options at 10,000,000 shares) and elected all director nominees. However, Proposal 3 (equity plan) saw significant opposition, with approximately 27.3 million votes against and only 61.2 million for.

• · Stockholders elected Jacob M. Chacko, M.D. with 89,298,150 votes for (vs. 408,106 withheld) and Mardi C. Dier with 82,007,899 votes for (vs. 7,698,357 withheld).
• · Proposal 2 (ratification of KPMG as auditor) passed overwhelmingly: 94,536,096 for, 34,641 against, 544 abstain, no broker non-votes.
• · Proposal 4 (advisory vote on executive compensation) passed with 88,453,809 for, 1,250,074 against, 2,373 abstain.
• · Proposal 5 (frequency of future advisory votes) approved 'every one year' with 89,392,979 votes for one year vs. only 6,986 for two years and 294,916 for three years; next such vote no later than 2032 annual meeting.
• · The amended 2020 Equity Incentive Plan also eliminated the administrator's ability to implement a program for surrendering/cancelling awards, transferring awards to third parties, or reducing exercise prices.

22-06-2026

Domino's Pizza Inc. announced a CEO succession plan: COO Joe Jordan will become CEO effective October 1, 2026, while current CEO Russell Weiner will transition to Executive Chairman after the 2027 annual meeting. Executive Chairman David Brandon will retire from the board in 2027 after 28 years of service. The leadership changes reflect a multi-year succession plan, with Weiner's tenure including net store growth of over 3,200 locations, nearly $3 billion in global retail sales growth, and close to a 30% increase in operating income.

• · Joe Jordan will join the Board of Directors on October 1, 2026.
• · Russell Weiner will serve as Executive Chairman Designate from October 1, 2026 until the 2027 annual shareholder meeting, then become Executive Chairman.
• · David Brandon served as CEO from 1999 to 2010 and as Chairman since 1999.
• · Domino's had more than 22,300 stores in over 90 markets as of the filing date.
• · Franchisees owned 99% of Domino's stores as of Q1 2026.
• · Over 85% of U.S. retail sales in 2025 were generated via digital channels.

22-06-2026

Huron Consulting Group Inc. elected Shoshana M. Vernick as a director effective June 19, 2026, to serve until the 2027 Annual Meeting. Ms. Vernick, co-founder and managing partner of Avathon Capital, brings expertise in education and knowledge services private equity. She will receive standard non-employee director compensation, including a prorated annual cash retainer of $80,000 and a prorated restricted stock grant valued at $90,000 (half of the annual $180,000 grant due to joining within six months of the annual meeting).

• · Ms. Vernick has been appointed to the Compensation Committee, Finance and Capital Allocation Committee, and Technology and Information Security Committee.
• · She will stand for re-election at the 2027 Annual Meeting.
• · Ms. Vernick serves as Vice Chair of the Illinois Venture Capital Association (IVCA) and is a founding Board member of the IVCA Foundation.
• · There are no arrangements or understandings between Ms. Vernick and any other persons regarding her election as a director, and she has no material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K.

22-06-2026

TaskUs, Inc. appointed Rishabh Khemka as Chief Financial Officer, effective June 19, 2026, bringing over 20 years of financial leadership from Encora and Wipro. Trent Thrash, who served as Interim CFO since March 2026, will return to his role as SVP of Corporate Development, Investor Relations and Treasury, reporting to Khemka. The filing does not include any financial results or performance metrics, so no period-over-period comparisons are available.

• · Rishabh Khemka most recently served as CFO at Encora, a digital engineering services firm backed by Advent International and Warburg Pincus, where he led financial integration after its acquisition by Coforge Limited.
• · Khemka spent over 18 years at Wipro, last serving as CFO of its Americas business.
• · Trent Thrash served as Interim CFO from March 2026 until Khemka's appointment.

22-06-2026

On June 15, 2026, Cheetah Net Supply Chain Service Inc. entered into a Securities Purchase Agreement with its CEO, Interim CFO, director, and Chairman Huan Liu, issuing 200,000 shares of Class B common stock at $2.00 per share for aggregate gross proceeds of $400,000. The transaction was conducted as a private placement exempt from registration under Regulation S and Section 4(a)(2)/Rule 506(b).

• · The issuance was made as a private placement exempt from registration under Regulation S and/or Section 4(a)(2) / Rule 506(b) of the Securities Act.
• · The Purchaser represented that the shares were acquired for investment purposes and not for distribution.
• · No general solicitation or advertising was used in the offer and sale.
• · The shares are restricted securities.
• · Company is an emerging growth company as defined under the JOBS Act.

22-06-2026

NVE Corporation announced CEO Daniel A. Baker will retire effective August 6, 2026, with Peter G. Eames appointed as his successor. The Board will expand from five to seven directors, adding Carolyn W. Valentine as a new nominee. The filing does not include any financial results or performance metrics.

• · Daniel A. Baker joined NVE in 2001 and led the company's transition from contract research to spintronics products.
• · Peter G. Eames has been Vice President of Advanced Technology since 2016 and an NVE employee since 2003.
• · Carolyn W. Valentine has been President of Grason-Stadler since October 2023.
• · The CEO change is effective at the Annual Shareholders' meeting on August 6, 2026.
• · Subject to shareholder approval, Dr. Baker will remain as Chairman, and Terrence W. Glarner will remain on the Board.

22-06-2026

Cohen & Company Inc. (COHN) disclosed that its indirect subsidiary, Cohen & Company Securities, LLC, entered into a Fourth Amendment to its existing Loan Agreement with Byline Bank on June 18, 2026. The amendment extends the maturity date to June 2028, updates definitions, and introduces a new Excess Net Capital covenant requiring at least $30 million (with a two-business-day cure period), while also increasing the required Tangible Net Worth from $70 million to $80 million effective March 31, 2027. No financial results or period-over-period comparisons are provided in this filing.

• · The amendment replaces certain definitions to reflect the Borrower's and its parent entity's current names.
• · Failure to maintain Excess Net Capital of at least $30 million constitutes an event of default, with a two-business-day cure period.
• · The maturity date and final loan availability date were extended from June 18, 2026 to June 18, 2028.
• · The required Tangible Net Worth increases from $70 million to $80 million effective after March 31, 2027.

22-06-2026

First Tracks Biotherapeutics (TRAX) entered into a sublease agreement with AnaptysBio on June 15, 2026, for approximately 45,057 rentable square feet at 10770 Wateridge Circle, San Diego, CA. The sublease has a 12-month initial term with an option to extend until April 4, 2028, and the company can terminate with three months' notice. The company is responsible for monthly Basic Rent plus Additional Rent under the Master Lease, but AnaptysBio remains primarily liable for the Master Lease obligations.

• · The sublease is subordinate to the Master Lease and will terminate immediately if AnaptysBio's tenancy under the Master Lease ends.
• · AnaptysBio cannot surrender or terminate the Master Lease before its scheduled expiration without the Company's consent (except for its own Termination Option).
• · The Company has the right to terminate the sublease at any time with at least three months' prior written notice.
• · The sublease commenced on June 15, 2026, and the filing was made on June 22, 2026.

22-06-2026

On June 16, 2026, BridgeBio Oncology Therapeutics held its Annual Meeting, where stockholders elected two Class I directors (Peter Lebowitz and Frank P. McCormick) and ratified Deloitte & Touche as independent auditor for FY2026. Director Michelle Doig resigned upon completion of her term, with no disagreement with the company. While director Lebowitz received overwhelming support (31,822,504 votes for), McCormick faced significant opposition with 6,171,757 votes withheld, representing about 19.4% of votes cast.

• · The company is an emerging growth company as defined under SEC rules.
• · Michelle Doig's resignation was effective June 16, 2026, upon completion of her term as a Class I director, and was not due to any disagreement with the company.
• · There were 13,805,126 no votes on both proposals, representing approximately 28.6% of shares present or represented by proxy.
• · Ratification of Deloitte & Touche was nearly unanimous with only 3,440 votes against and zero abstentions.

22-06-2026

On June 15, 2026, AnaptysBio subleased approximately 45,057 rentable square feet of its San Diego headquarters to First Tracks Biotherapeutics for an initial 12-month term, with First Tracks paying monthly rent equal to the basic rent and additional rent under the master lease. However, AnaptysBio remains primarily liable for all rent and obligations under the master lease, and the sublease terminates if the company's tenancy ends for any reason. The filing discloses a material sublease agreement but includes no financial terms beyond the pass-through of master lease rent obligations.

• · Sublease term commenced June 15, 2026 and runs for 12 months.
• · First Tracks has a renewal option from end of initial term until earlier of April 4, 2028 or 12 months from renewal start, with 3 months' notice.
• · First Tracks can terminate the sublease at any time with at least 3 months' written notice.
• · The sublease is subordinate to the existing master lease dated May 4, 2020 (as amended April 5, 2021).
• · AnaptysBio cannot surrender or terminate the master lease without First Tracks' consent (except via the master lease's Termination Option).

22-06-2026

STAAR Surgical Company held its 2026 Annual Meeting on June 18, 2026, where shareholders approved an amendment to the Omnibus Equity Incentive Plan to increase authorized shares by 3.9 million. All seven director nominees were elected, and the appointment of BDO USA as auditor was ratified. However, the non-binding advisory vote on executive compensation received 1.45 million against votes (3.5% of votes cast), indicating some shareholder dissent.

• · Shareholders approved the equity plan amendment with 40.2M for, 975K against, and 67.9K abstentions.
• · The non-binding advisory vote on executive compensation (Proposal 4) had 39.7M for, 1.45M against, and 82.8K abstentions.
• · All seven director nominees received over 40 million votes each, with the lowest being 40.5M for Louis E. Silverman.
• · BDO USA was ratified as auditor with 43.4M for, 237K against, and 10K abstentions (no broker non-votes).

22-06-2026

Pluri Inc. entered into an Advance Subscription Agreement with Chutzpah Holdings LP, beneficially owned by Chairman Alexandre Weinstein, receiving an advance of $1,250,000 for working capital. The advance is intended to be credited toward a future offering to be consummated by August 14, 2026, but if not, the unapplied amount will be applied to other securities purchases. Additionally, at the 2026 Annual Meeting, director Eitan Ajchenbaum was not re-elected (2,830,098 for vs. 3,668,436 against), and Doron Shorrer was appointed to fill the vacancy, serving as Audit Committee Chair and Investment Committee sole member.

• · The Advance Amount of $1,250,000 was received on June 16, 2026.
• · The Offering must be consummated on or before August 14, 2026, or the unapplied advance will be applied to other securities purchases.
• · Eitan Ajchenbaum received 2,830,098 votes for and 3,668,436 votes against, failing re-election.
• · Doron Shorrer, age 73, is a founder of the Company and previously served as a director until June 2022.
• · Mr. Shorrer holds a B.A. in Economics and Accounting and an M.B.A. in Finance and Banking from Hebrew University and is a CPA in Israel.
• · The ratification of PwC as auditor received 7,558,826 votes for, 20,364 against, and 2,007 abstentions.
• · The Company's common shares trade on Nasdaq under symbol PLUR.

22-06-2026

On June 15, 2026, BPM LLP resigned as Datavault AI Inc.'s independent registered public accounting firm effective immediately. The company is in the process of selecting a successor. BPM's reports for fiscal years 2024 and 2025 were unqualified, and there were no disagreements or reportable events during the relevant periods.

• · BPM's resignation was effective immediately on June 15, 2026.
• · No adverse opinions, disclaimers, or modifications were issued by BPM for fiscal years 2024 and 2025.
• · No disagreements or reportable events occurred during fiscal years 2024, 2025, or the interim period through June 15, 2026.
• · The company has not yet selected a successor auditor and will disclose the engagement once completed.
• · A letter from BPM dated June 22, 2026, agreeing with the company's disclosures, is filed as Exhibit 16.1.

22-06-2026

Mary A. Tidlund notified Valhi, Inc. on June 17, 2026 of her resignation as a director, effective June 30, 2026. The resignation did not result from any disagreement with the company. No financial figures or period-over-period data are provided in this filing.

22-06-2026

indie Semiconductor announced the resignation of co-founder Dr. Ichiro Aoki as President and board member effective June 29, 2026, transitioning him to a Technical Advisor role. Thomas Schiller, former CFO and Strategic Advisor, has been appointed to the Board of Directors to support strategic execution as the company expands into adjacent physical AI markets including robotics and humanoids.

• · Dr. Aoki has been with indie since its inception as a co-founder and oversaw engineering plan execution.
• · Thomas Schiller previously served as indie's CFO and Executive Vice President of Strategy until June 2024, leading financing, reporting, investor relations, treasury, tax, and M&A.
• · Schiller has been a Strategic Advisor to indie since November 2024, providing guidance in strategic planning and M&A.
• · Schiller played an instrumental role in steering indie's 2021 IPO.
• · Schiller holds an MBA from USC specializing in Entrepreneurship and Finance, and a BA from UC Irvine; he also completed executive education at UCLA and MIT.

22-06-2026

TD SYNNEX appointed Douglas Britt to its Board of Directors, effective June 17, 2026, increasing the board size from ten to eleven members. Britt, a seasoned technology executive with over 30 years of experience, will serve on the Audit and Technology Committees. The appointment strengthens governance and strategic oversight, particularly in hyperscale digital infrastructure, but no negative or flat performance metrics were disclosed in this filing.

• · Britt currently serves as Executive Chairman of Boyd, having previously led the sale of Boyd Thermal business to Eaton Corporation in 2026.
• · Britt currently serves on the boards of Helios Technologies and Benchmark Electronics.
• · Britt holds a Bachelor of Science in Business Administration from California State University, Chico, and completed executive education programs at the University of London.
• · TD SYNNEX is a Fortune 100 company with a comprehensive edge-to-cloud portfolio spanning cybersecurity, analytics, artificial intelligence, mobility, and Everything-as-a-Service.

22-06-2026

Mary A. Tidlund notified CompX International Inc. of her resignation as a director, effective June 30, 2026. The resignation did not result from any disagreement with the company. No financial impact or other operational changes were disclosed.

• · Resignation effective date: June 30, 2026
• · No disagreement with the company was cited as reason for departure
• · Filing date: June 22, 2026

22-06-2026

Comfort Systems USA announced leadership transitions effective July 1, 2026, including the appointment of Craig Sasser as Chief Operating Officer and Briston Blair as Chief Strategy & Innovation Officer. Trent T. McKenna will continue as President. The changes reflect internal promotions aimed at long-term growth, but no financial or operational performance data was disclosed in this filing.

• · Craig Sasser has been with Comfort Systems since September 2018, previously serving as Regional Vice President for the North and Atlantic regions.
• · Briston Blair has served as Senior Vice President – Innovation & Strategy since January 2022, and previously held roles including Regional Vice President and Senior Growth Strategy & Corporate Development Advisor.
• · No financial metrics, revenue changes, or performance comparisons were provided in this filing.

22-06-2026

Firefly Neuroscience, Inc. (AIFF) filed an 8-K on June 22, 2026, reporting that Gil Issachar, formerly Chief Technology Officer, transitioned to Head of AI and Neuroscience effective June 18, 2026, via an employment agreement with Deel Innovation Ltd. As a result, Issachar is no longer classified as a Section 16 officer or executive officer. No financial figures or performance metrics were disclosed in this filing.

• · Issachar's employment agreement includes a Determined Salary of ILS 50,000 per month (Base Salary ILS 48,000 + Global Overtime Consideration ILS 2,000).
• · A total outstanding bonus of ILS 131,250 is payable in 20 equal monthly installments of ILS 6,562.5 each.
• · The role is full-time (minimum 42 hours per week) with a remote work location in Israel.
• · Annual vacation leave is 22 days per year with carryover allowed.
• · Notice period is 30 days from start date.
• · The agreement is not subject to a probationary period.
• · Company contributes 7.5% of Determined Salary to an Education Fund (Keren Hishtalmut), with employee contributing 2.5%.

22-06-2026

HeartBeam, Inc. granted its President and Founder Branislav Vajdic a performance-based restricted stock unit award of 2,800,000 RSUs and a transaction bonus agreement tied to market capitalization thresholds. The PRSU vests based on operational milestones and service conditions, while the transaction bonus pays up to 2% of Aggregate Price Paid if market cap exceeds certain undisclosed thresholds. No financial results or period comparisons are included.

• · The PRSU award is under the 2022 Equity Incentive Plan.
• · Performance conditions relate to operational, software, product-development and clinical study milestones within one year of grant.
• · Service-based vesting occurs one-third on each of first three anniversaries, with accelerated vesting upon Change in Control.
• · Transaction bonus is 1% of Aggregate Price Paid if market cap is at least [***], plus additional 0.5% for each of two higher thresholds.
• · No bonus payable if market cap is below the minimum threshold.
• · Bonus is paid in same form as stockholder consideration, but Board may elect cash.
• · Payment within 30 days after closing; post-closing payments subject to same terms as stockholders, forfeited if not paid by 5th anniversary.
• · Agreement terminates upon completion of payments, first Qualifying Change in Control with $0 bonus, termination of employment before Change in Control, or Expiration Date.

22-06-2026

Dyne Therapeutics elected Barry E. Greene as a Class I independent director on June 22, 2026, to serve until the 2027 Annual Meeting. He received an option to purchase 57,463 shares at $20.87 per share, vesting over three years, and annual cash compensation of $45,000. No other material changes or negative developments were disclosed.

• · Mr. Greene has not been appointed to any Board committees.
• · The option vests in equal monthly installments over three years, with full acceleration upon a change in control.
• · Mr. Greene will also receive annual equity grants under the non-employee director compensation program and reimbursement for travel expenses.
• · No arrangements or understandings exist between Mr. Greene and any other person regarding his election.
• · No family relationships with directors or executive officers, and no related-party transactions requiring disclosure.

22-06-2026

Genvor Inc entered into a side letter agreement with Evergreen Capital Management LLC on June 17, 2026, amending the prior securities purchase agreement. The amendment deletes Evergreen's registration rights, increases warrant coverage from 600,000 to up to 1,200,000 shares, and accelerates funding of the second and third tranches, providing the company with $333,334 in gross proceeds on the effective date. However, the fourth tranche of $166,667 is now solely at Evergreen's option, introducing uncertainty about full funding of the $800,000 note.

• · The warrant has a five-year term and an exercise price of $1.00 per share, subject to adjustment.
• · After the six-month anniversary of issuance, if the market price exceeds the exercise price and the warrant shares are not registered, Evergreen may exercise on a cashless basis.
• · The fourth tranche option expires on the maturity date of the note.
• · Evergreen retains $10,000 from each tranche for legal fees and closing costs.

22-06-2026

Five9, Inc. announced the planned departure of Panos Kozanian, Executive Vice President of Product Engineering, effective June 29, 2026, with a transition period through at least September 4, 2026. The company will announce a new Chief Technology Officer by the end of Q2 2026. Mr. Kozanian will remain eligible for severance benefits under the Key Employee Severance Plan unless terminated for cause.

• · Transition effective June 29, 2026; Mr. Kozanian expected to serve through at least September 4, 2026.
• · New CTO to be announced by end of Q2 2026.
• · Mr. Kozanian is a Tier 3 participant in the Key Employee Severance Plan.

22-06-2026

Best Buy announced that CFO Matt Bilunas will step down on July 31, 2026, after 20 years with the company, including seven as CFO. The company has engaged an external search firm to find a successor with previous CFO experience, while current CEO Corie Barry—herself a former CFO—will provide financial oversight during the transition if needed. Bilunas leaves as Best Buy generated $41.7 billion in revenue in fiscal 2026 and operates over 1,000 stores with more than 80,000 employees, and incoming CEO Jason Bonfig takes over on November 1, 2026.

• · Bilunas joined Best Buy in July 2006 as a Territory Finance Director and held roles including SVP of Enterprise Finance before becoming CFO in 2019.
• · Bilunas was responsible for finance, enterprise strategy, procurement, financial services, real estate, and omnichannel operations.
• · Best Buy is the world's largest specialty consumer electronics retailer.

22-06-2026

Arvinas, Inc. announced the departure of Chief Medical Officer Noah Berkowitz, M.D., Ph.D., effective July 3, 2026, to pursue other opportunities. The company has begun a search for a replacement. Dr. Berkowitz will receive severance benefits including nine months of base salary and health coverage, plus accelerated vesting of certain RSUs that would have vested on or before May 9, 2027; all other unvested RSUs will be forfeited.

• · Departure effective date: July 3, 2026
• · Separation agreement includes release of claims, continued compliance with proprietary information and assignment agreement, confidentiality, cooperation, and non-disparagement obligations
• · Accelerated vesting applies only to RSUs that would vest on or before May 9, 2027; all other unvested RSUs are forfeited
• · Acceleration of vesting is subject to taxation and applicable withholdings
• · The full separation agreement will be filed with the Form 10-Q for the quarter ending June 30, 2026

22-06-2026

PagerDuty, Inc. (NYSE: PD) announced the appointment of Eric Prengel as Chief Financial Officer, effective June 22, 2026. He succeeds Howard Wilson, who is retiring before the end of the second quarter of fiscal 2027 (July 31, 2026). Prengel brings over 20 years of leadership experience from Elastic, JPMorgan, and Deutsche Bank, and will oversee finance, business operations, corporate strategy, development, and investor relations. The filing highlights PagerDuty's AI-first operations management platform, which serves approximately two-thirds of the Fortune 100 and nearly half of the Fortune 500.

• · Eric Prengel earned his bachelor's degree from the University of Pennsylvania in economics.
• · Howard Wilson is retiring before the end of Q2 FY2027 (July 31, 2026).
• · PagerDuty serves approximately two-thirds of the Fortune 100 and nearly half of the Fortune 500.